Read Summary

Phase 2 findings suggest nab-paclitaxel plus gemcitabine-cisplatin may prolong survival in advanced biliary tract cancers. However, experts urge caution until a phase 3 trial is completed.
Medscape Medical News

Print Friendly, PDF & Email